Fact-checked by Grok 2 weeks ago

Ernst Chain

Ernst Boris Chain (19 June 1906 – 12 August 1979) was a German-born biochemist who shared the 1945 in Physiology or Medicine with and for the and its curative effects against bacterial infections. Born in to a Jewish family, with his father a and industrialist, Chain studied and physiology at Friedrich-Wilhelm University, graduating in 1930 before emigrating to Britain in 1933 amid rising Nazi persecution. At the University of Oxford's Sir William Dunn School of Pathology, Chain collaborated with Florey to purify and characterize penicillin—a substance first noted by Fleming—demonstrating its antibacterial potency through systematic extraction, chemical analysis, and animal testing that confirmed its therapeutic potential. Chain's biochemical expertise enabled the large-scale production of penicillin during World War II, which proved vital in treating infected wounds and saving countless lives, particularly among Allied soldiers. He also identified penicillinase, an enzyme produced by certain bacteria that inactivates penicillin, highlighting early challenges in antibiotic resistance. Following the war, Chain advanced research on other natural antibiotics, snake venom components, and tumor metabolism, serving as professor of biochemistry at Imperial College London from 1948 and founding the International Research Centre for Chemical Microbiology in 1961. Knighted in 1970, his work underscored the causal mechanisms linking microbial metabolites to disease treatment, emphasizing rigorous chemical isolation over serendipity in scientific discovery.

Early Life and Education

Birth and Family Background

Ernst Boris Chain was born on June 19, 1906, in , , into a Jewish family of Russian-German descent. His father, Dr. Michael Chain, was a and who had emigrated from to to pursue studies in , eventually establishing a successful manufacturing chemical products. His mother, Margarete Chain (née Eisner), was born in and came from a German Jewish background. Michael Chain's professional success provided the family with relative affluence in pre-World War I Berlin, though the household emphasized intellectual pursuits aligned with their Jewish cultural heritage. Chain had at least one sister, who, like their mother, remained in Germany after his emigration and perished during the Holocaust. His father died in 1919, when Chain was 13 years old, leaving a formative impact on the young boy's interest in chemistry and science. This early loss, amid the family's Jewish identity, later underscored the urgency of Chain's flight from Nazi persecution.

Studies in Berlin

Chain enrolled at the Friedrich-Wilhelm University in in 1924, pursuing studies in and . His early interest in biochemistry, stimulated by visits to his father's chemical laboratory and factory, directed his academic focus toward and its biological applications. During his time at the university, Chain conducted research that culminated in a doctoral dissertation on the chemical and enzymatic properties of proteins, particularly their behavior under denaturation. This work emphasized experimental approaches to understanding molecular structures, reflecting the era's advancements in applied to biological systems. He graduated with a in chemistry and physiology in 1930. Chain's education in Berlin provided a rigorous foundation in quantitative analysis and biochemical techniques, though the rising political tensions in Germany, including increasing antisemitism, began to influence his career prospects by the early 1930s. His training under prominent faculty equipped him with skills in protein chemistry that later proved instrumental in his microbiological research.

Emigration and Pre-War Career

Flight from

In early 1933, following Hitler's appointment as Chancellor on January 30 and the rapid enactment of antisemitic policies by the regime, Ernst Chain, a 26-year-old Jewish , decided to emigrate from to avoid impending persecution. Chain had recently completed his doctoral studies in chemistry and physiology at Friedrich-Wilhelm University in , earning his Ph.D. in , and was employed at the Institute for Muscle Chemistry in the city, conducting research on biochemical effects. As a Jew in a field dominated by state-funded institutions, Chain faced exclusion under emerging racial laws, including the April 7, 1933, Law for the Restoration of the Professional Civil Service, which barred Jews from civil service positions, effectively purging them from academia and research roles. Chain departed Berlin shortly after the Nazis consolidated power, arriving in by early 1933 with minimal resources, having secured an invitation to continue his work on phospholipids at the University of Cambridge's School of Biochemistry under Professor Frederick Gowland Hopkins. His emigration was proactive, driven by awareness of the regime's escalating hostility toward , though he was unable to extract his mother, Margarete Chain, or his sister from ; both later perished in . This flight exemplified of over 2,000 German Jewish scientists and intellectuals in 1933 alone, many of whom contributed significantly to Allied scientific advancements during .

Arrival and Initial Work in Britain

Chain emigrated from to in early 1933, arriving on with only £10 after the Nazi regime's rise to power rendered his position untenable as a Jew. He initially secured a temporary position in the department of chemical pathology at Medical School in , under biochemist Charles Harington, where facilities were limited. Assisted by geneticist , who recommended him to Nobel laureate Frederick Gowland Hopkins, Chain transferred to the Department of Biochemistry at the later in 1933. There, for approximately two years, he conducted research on snake venoms and phospholipids, building on his prior expertise in and enzymology from . This period allowed Chain to adapt to British scientific methods while exploring biochemical mechanisms, including the isolation and analysis of venom components for potential therapeutic applications. By 1935, seeking expanded opportunities in and , Chain relocated to the to join Howard Florey's team, marking the transition from foundational biochemical studies to applied antibiotic research. His early British work demonstrated resilience amid emigration challenges, laying groundwork for interdisciplinary contributions without immediate recognition.

Development of Penicillin

Revival of Fleming's Discovery

In 1939, while researching antibacterial substances at the University of Oxford's Sir William Dunn School of Pathology under , Ernst Chain encountered Alexander Fleming's 1929 paper describing the inhibitory effects of Penicillium notatum mold on staphylococci. Chain, a with expertise in , proposed to Florey that they attempt to purify and characterize the active compound, penicillin, as part of their broader investigation into and other antimicrobial agents. This initiative revived Fleming's largely overlooked discovery, which had stalled due to challenges in isolating the unstable substance in sufficient quantities for therapeutic use. Chain and Florey quickly replicated Fleming's observations, confirming penicillin's bacteriostatic properties against various while noting its ineffectiveness against Gram-negative strains. By early 1940, Chain had developed methods to extract and partially purify penicillin from culture filtrates using acid precipitation and solvent partitioning, yielding a more concentrated form than Fleming's crude preparations. Their systematic approach transformed penicillin from a laboratory curiosity into a candidate for clinical evaluation, with Chain's chemical techniques proving crucial in stabilizing the compound for further testing. The revival gained momentum through animal trials initiated on May 25, 1940, when Florey and Chain infected eight mice with lethal doses of streptococci; four treated with penicillin survived, demonstrating its efficacy and potential to combat systemic infections. Chain's concurrent discovery of penicillinase, an produced by certain that degrades penicillin, highlighted early challenges like resistance mechanisms, informing subsequent refinements. This phase marked the shift from empirical observation to rigorous biochemical development, laying the groundwork for penicillin's wartime production.

Purification, Testing, and Production

Following initial confirmation of penicillin's antibacterial properties, Ernst Chain, in collaboration with Edward Penley Abraham, developed a purification technique involving of the culture filtrate with solvents such as or amyl acetate after acidification to 2, followed by re- into an aqueous phase upon neutralization to 7-8. This method produced a crude, brownish powder with potency estimated at 20-60 units per milligram, sufficient for biological assays but not yet suitable for large-scale therapeutic use. Purity was assessed via bioassays measuring inhibition zones on plates seeded with susceptible bacteria like . In vitro testing demonstrated penicillin's efficacy against Gram-positive bacteria including streptococci and staphylococci, while it showed limited activity against Gram-negative organisms. Animal testing commenced in May 1940, when Chain and Howard Florey's team infected ten mice with a lethal dose of Streptococcus pyogenes; five received penicillin injections every two hours for ten doses and survived, whereas the five untreated controls succumbed within two days. These results, published in The Lancet on 24 August 1940, confirmed penicillin's potential as a systemic chemotherapeutic agent. For production, Norman Heatley, working under Florey and Chain, optimized culture conditions using surface in shallow vessels such as ceramic bedpans or enamel trays to maximize mold growth, yielding approximately 1-2 milligrams of impure penicillin per liter of medium after . Chain's biochemical expertise facilitated the scaling of these processes in a at , though yields remained low—around 100-200 mg per batch—limiting supply to experimental needs by early 1941. These efforts enabled the first human trials but highlighted the necessity for methods developed later in the United States.

Wartime Applications and Challenges

Following successful mouse experiments in May 1940, which demonstrated penicillin's ability to combat lethal streptococcal infections, Chain and Florey conducted the first human trial in February 1941 on Albert Alexander, a policeman with severe facial wounds from a shard of glass, resulting in partial recovery but ultimate death on March 15 due to insufficient drug quantities available for sustained treatment. These early tests highlighted penicillin's efficacy against bacterial infections common in war wounds, such as those causing and , prompting urgent efforts to scale production for Allied military needs amid rising battlefield casualties. Initial production challenges in Britain stemmed from low yields—typically 2 to 4 Oxford units per milliliter of culture—and labor-intensive purification processes involving solvent extraction and repeated freeze-drying, which Chain refined but proved inadequate for mass needs under wartime constraints like resource shortages and bombing risks. British pharmaceutical firms, including ICI, declined large-scale involvement due to inability to prioritize amid munitions demands, leading Florey to seek U.S. collaboration in June 1941 with Norman Heatley, where the War Research Service at Peoria's Northern Regional Research Laboratory advanced techniques using corn steep liquor as a nutrient medium and submerged aerobic fermentation in deep tanks to boost yields dramatically. Chain continued biochemical assays and stability studies at Oxford, but the shift to American industrial production—exemplified by Pfizer's first commercial deep-tank facility opening on March 1, 1944—addressed contamination risks and aeration issues that had plagued surface cultures. By late 1943, penicillin output reached 400 million units monthly, enabling its deployment in campaigns like and , where it reduced infection mortality from over 75% to under 10% in treated wound cases, with stockpiles of 2.3 million doses available for the D-Day invasion on June 6, 1944. Wartime secrecy classified production details until March 1944, limiting broader applications, while ethical dilemmas arose from the scarce supply strictly for , postponing civilian access until after V-E Day in May 1945 despite demonstrated life-saving potential in non-combat infections. These efforts, though spearheaded by U.S. firms under government contracts, built directly on Chain's foundational purification work, ultimately contributing to an estimated 12-15% drop in overall bacterial infection fatalities among Allied troops.

Nobel Prize and Recognition

The 1945 Award

The Nobel Prize in Physiology or Medicine for 1945 was awarded jointly to Sir , Ernst Boris Chain, and Sir Howard Walter Florey on October 15, 1945, recognizing their contributions to the and demonstration of its curative effects against various infectious diseases. The official motivation specified "for the and its curative effect in various infectious diseases," with Chain's role emphasized in the chemical purification and systematic production of the substance alongside Florey and their team beginning in the early . The award ceremony occurred on December 10, 1945, in Stockholm, where the laureates received the prize from King Gustaf V of Sweden. In the presentation speech by Professor A. von Euler, Chain was described as the chemist who participated in the final investigative stages, collaborating with Florey to advance the practical application of penicillin after initial observations by Fleming in 1928. Chain shared the prize equally with his co-recipients, each receiving one-third of the monetary award, which totaled 150,792 Swedish kronor that year. At the Nobel Banquet, Chain addressed the assembly, expressing gratitude and underscoring the collaborative nature of the penicillin research amid wartime exigencies.

Disputes over Credit and Contributions

The 1945 Nobel Prize in Physiology or Medicine was awarded jointly to , Ernst Chain, and "for the and its curative effects in various infectious diseases," recognizing Fleming's initial 1928 observation of the mold's antibacterial properties alongside the team's advancements in , purification, and . However, public narratives often emphasized Fleming as the singular "discoverer," leading to ongoing debates about the relative contributions, with Chain and Florey expressing private frustration over the attribution. Chain, known for his abrasive personality and acute sensitivity, contended that Fleming's finding was largely serendipitous and inadequately pursued, lacking the systematic biochemical analysis and proof-of-principle experiments that his own work with Florey provided, such as demonstrating penicillin's in mice infected with streptococci on May 25, 1940. He frequently clashed with Florey over internal credit within the Oxford group, arguing that his expertise in chemistry was pivotal to identifying penicillin as a stable organic molecule rather than an unstable , as initially hypothesized. These tensions persisted despite their collaboration yielding the first therapeutic successes, including limited human trials in , and Chain later reflected that the true lay in the developmental rigor absent from Fleming's earlier efforts.

Later Career and Research

Post-War Work in Italy

In 1947, Chain relocated from to , where he was appointed head of the newly established biochemistry department at the Istituto Superiore di Sanità (ISS), Italy's , and director of a for penicillin production. In 1948, he additionally became Scientific Director of the International Research Centre for Chemical Microbiology at the ISS, a role that facilitated international collaborations and positioned the institute as a hub for research. His move addressed Italy's acute post-war shortage of penicillin, as the country lacked domestic production capacity amid economic devastation and reliance on imports, prompting the use of UNRRA (United Nations Relief and Rehabilitation Administration) funds to build infrastructure. Chain oversaw the design and construction of a state-sponsored penicillin factory at the ISS, with foundations laid in February 1948 despite delays from bureaucratic disorganization, site clearance, and competition from private pharmaceutical firms like Leo and Squibb. Production commenced in June 1952, achieving an output of 950 billion units (OU) per year by 1955 through Chain's advancements in controlled submerged processes, which minimized batch failures and improved yield stability. He also patented a two-dimensional chromatographer for purifying antibiotics and collaborated with the (WHO) and Italian firms to transfer technology, though a non-commercial clause limited market expansion and the plant's long-term viability against imported alternatives. Beyond production, Chain's research at the ISS emphasized chemical , including the isolation of 6-aminopenicillanic acid () in 1959, a core intermediate enabling the synthesis of penicillinase-resistant and broad-spectrum penicillins that transformed antibiotic . He investigated technologies for lysergic acid production in submerged cultures, isolated novel fungal metabolites, and explored carbohydrate-amino acid interactions in alongside insulin's , fostering biochemical advancements amid Italy's rebuilding scientific landscape. Chain remained at the ISS until 1961, resigning formally in 1964, during which his leadership elevated the institute's global profile despite persistent and infrastructural hurdles.

Return to the United Kingdom

In 1964, after directing biochemistry research at the Istituto Superiore di Sanità in since 1948, Ernst Chain returned to the to establish and lead the newly created Department of Biochemistry at . He insisted on incorporating a for large-scale studies, enabling applied biochemical investigations akin to his wartime penicillin work. Chain held the professorship until his formal retirement in , though he remained active in thereafter. His efforts at focused on expanding biochemical capabilities, including studies on mechanisms, actions, and metabolic pathways, building on his prior expertise in microbial products and protein chemistry. The department's growth under his leadership solidified 's prominence in biochemistry, with Chain mentoring students and fostering interdisciplinary collaborations. In recognition of his sustained contributions to , Chain was knighted in 1970 as Sir Ernst Chain. This period marked a return to his adopted homeland, where he prioritized empirical biochemical inquiry over emerging trends he critiqued elsewhere in his career.

Additional Scientific Investigations

Chain's post-war research encompassed biochemical analyses beyond antibiotics, including the chemical composition of components and their toxicological mechanisms. He demonstrated that neurotoxic effects from venoms of such as the cobra (Naja naja) and black tiger snake (Notechis scutatus) stem from inhibition of fermentative processes; experiments showed these venoms suppressed tissue fermentation , an effect neutralized by specific antisera that also mitigated toxicity. This work, initiated during his Oxford tenure and continued later, highlighted enzymatic disruptions as a basis for . A significant focus was the of insulin, probing its metabolic influences at the cellular level. Chain examined insulin's role in glucose metabolism, including experiments on its effects alongside cardiac activity on the incorporation of radiolabeled glucose into tissues, aiming to elucidate insulin's biochemical pathways in carbohydrate utilization. Complementary studies addressed insulin's molecular structure, contributing to early insights into its peptide composition and physiological regulation. Chain further investigated , termed the "spreading factor," an that depolymerizes to enhance permeability and substance , with implications for spread and therapeutic delivery. His broader inquiries included carbohydrate-amino acid interactions in , general mechanisms, and applications to tumor , yielding advancements in biochemical methodologies for isolation and metabolic tracing. These efforts, often conducted at the Istituto Superiore di Sanità in from 1948 onward, reflected Chain's emphasis on integrating chemical analysis with physiological function.

Scientific Philosophy and Criticisms

Views on Molecular Biology and Biochemistry

Chain held that the burgeoning field of , while valuable for elucidating genetic mechanisms, threatened to marginalize biochemistry's foundational role in understanding metabolic pathways, functions, and physiological integration essential to medical applications. He argued that an overemphasis on DNA-centric approaches risked neglecting the broader biochemical contexts of cellular and organismal , particularly in disease and . In establishing the Department of Biochemistry at in 1964, Chain explicitly refused to appoint molecular biologists to his staff, prioritizing researchers versed in classical biochemical techniques such as protein isolation, processes, and studies. This stance reflected his commitment to "physiological whole-animal biochemistry," which he viewed as complementary to, rather than supplanted by, molecular reductions. Chain's advocacy extended to critiques of disciplinary silos in research funding and during the 1960s and 1970s, where he warned that privileging could undermine interdisciplinary progress in antibiotics, venoms, and tumor biochemistry—fields where his own work had yielded practical insights. He emphasized biochemistry's empirical strengths in scaling laboratory findings to therapeutic realities, as demonstrated in his penicillin purification efforts and later investigations into snake venom neurotoxins, which required integrating molecular structures with systemic physiological effects. Chain maintained that true advances in demanded this holistic biochemical lens, cautioning against the "expense of other disciplines" in pursuit of genetic .

Political Stance and Broader Influences

Chain's political outlook was profoundly influenced by his and the trauma of Nazi . Born into a secular Jewish family in , he emigrated to in shortly after the Nazi seizure of power, recognizing the imminent threat to ; his mother and sister remained behind and perished in concentration camps during . This experience instilled in him a deep-seated opposition to , manifesting in a commitment to and the defense of Jewish peoplehood. Later in life, Chain embraced , raising his children within the faith and arranging supplementary for them, which reflected a deliberate reclamation of heritage amid secular scientific circles. His views on Jewish identity were most explicitly outlined in the 1965 speech "Why I Am a Jew," delivered at the World Jewish Congress Conference of Intellectuals in Jerusalem, where he affirmed Judaism's enduring ethical and cultural significance against assimilationist pressures. Chain rejected both extreme secularism and uncritical religious dogma, advocating instead for a synthesis where faith informed moral reasoning without compromising empirical inquiry—a stance that positioned him against ideologies subordinating individual liberty to state or ideological collectivism, as seen in Nazism. While no explicit endorsements of partisan politics are recorded, his wartime and postwar advocacy for applied science in national defense, including efforts to establish antibiotic industries free from bureaucratic overreach, aligned with pragmatic anti-totalitarian priorities over ideological experimentation. Broader influences on Chain included classical philosophy and a holistic that resisted materialist . Early exposure to Berlin's intellectual milieu, including for a left-leaning in his youth, gave way to a mature perspective emphasizing and , critiquing Darwinian as speculative and unproven: "I would rather believe in fairies than in such wild speculation." This philosophical extended to atheistic , which he viewed as ethically barren when confined to description without prescriptive moral anchors derived from transcendent sources like . His 1961 visit to amid tensions, focused on technology transfer, demonstrated a utilitarian approach to scientific that prioritized human welfare over geopolitical alignment, underscoring influences from tempered by .

Personal Life and Legacy

Family, Interests, and Character

Ernst Boris Chain was born on 19 June 1906 in to a Jewish family of mixed origins. His father, Dr. Michael Chain, was a and industrialist who had immigrated from and established a chemical manufacturing business, while his mother, Margarete Eisner, was a Berlin native. Chain's father died when he was 13 years old, precipitating a sharp decline in the family's financial circumstances that influenced his early determination to pursue a scientific career. In 1948, Chain married Anne Beloff, a and sister of political scientist Max Beloff; the couple had two sons and one daughter. Chain regarded his marriage as a source of great personal happiness, and the family relocated with him during his professional moves, including to in the 1950s. From his youth, Chain exhibited a profound interest in music, training as a and briefly aspiring to a career as a performer, including public recitals during his years. He maintained this passion lifelong, achieving expertise on and occasionally performing publicly alongside his elder son, with music ranking among his principal non-scientific pursuits. Chain possessed a confident self-assurance in his scientific abilities paired with a volatile that occasionally led to interpersonal tensions in collaborative settings. His early experiences, including the loss of family wealth and the rise of in prompting his 1933 emigration, fostered a resilient and driven character oriented toward empirical rigor in research.

Death and Enduring Impact

Chain died of on August 12, 1979, at Mayo General Hospital in , , at the age of 73, after falling ill at his country home in Mulranny, . Chain's enduring impact stems primarily from his pivotal role in developing penicillin into a viable therapeutic agent during , which transformed infectious disease treatment and saved countless lives by enabling large-scale production of the . Alongside , Chain purified and chemically characterized penicillin, elucidated its mode of action against , and devised methods for its industrial synthesis, earning them shared credit in the 1945 in Physiology or with —recognition that underscored Chain's biochemical innovations beyond Fleming's initial observation. This work laid foundational principles for modern therapy, influencing subsequent and reducing mortality from bacterial infections globally. Beyond penicillin, Chain's later research on snake venom components, tumor metabolism, and carbohydrate biochemistry advanced understanding of enzymatic processes and potential anticancer agents, though these contributions received less immediate acclaim than his wartime achievements. His emphasis on rigorous chemical analysis over purely empirical approaches exemplified a commitment to mechanistic insight in biochemistry, shaping scientific methodology in and research. Chain's knighthood in 1969 by Queen Elizabeth II further affirmed his stature in British science.

References

  1. [1]
    The Nobel Prize in Physiology or Medicine 1945 - NobelPrize.org
    The Nobel Prize in Physiology or Medicine 1945 was awarded jointly to Sir Alexander Fleming, Ernst Boris Chain and Sir Howard Walter Florey
  2. [2]
    Ernst B. Chain – Facts - NobelPrize.org
    Ernst Boris Chain, Howard Florey, and their colleagues succeeded in systematically producing a pure form of penicillin at the beginning of the 1940s.
  3. [3]
    Ernst B. Chain – Biographical - NobelPrize.org
    Ernst Boris Chain was born on June 19, 1906, in Berlin, his father, Dr. Michael Chain, being a chemist and industrialist. He was educated at the Luisengymnasium ...
  4. [4]
    Howard Walter Florey and Ernst Boris Chain | Science History Institute
    After Alexander Fleming's 1928 discovery of penicillin, Florey and Chain's further research enabled the testing and production of the drug.
  5. [5]
    Ernst B. Chain – Banquet speech - NobelPrize.org
    ... penicillin which has helped to alleviate the suffering of the wounded soldiers of Britain, the country that has adopted me, and the wounded soldiers of our ...
  6. [6]
    Ernst Chain—Nobel Prize for Work on Penicillin
    Chain also discovered penicillinase, an enzyme that catalyzes the destruction of penicillin.<|separator|>
  7. [7]
    Sir Ernst Chain: Penicillin Pioneer - University College Oxford (Univ)
    Jan 20, 2021 · Whilst at Oxford Chain collaborated with Howard Florey in their groundbreaking research into penicillin, and were able to prove its importance ...
  8. [8]
    A Science Odyssey: People and Discoveries: Ernst Chain - PBS
    Ernst Chain's father came from Russia to Germany to study chemistry. He stayed there, marrying a Berliner and starting a successful chemical manufacturing ...Missing: background | Show results with:background
  9. [9]
    1906: Nobel-winning Penicillin Researcher Is Born - Jewish World
    Jun 19, 2013 · Ernst Boris Chain was born in Berlin, to chemist and industrialist Michael Chain and the former Margarete Eisner, both of them Jews. Michael ...
  10. [10]
    Chain, Professor Sir Ernst Boris | Wellcome Collection
    Biographical note​​ Chain was born in 1906 in Berlin where his Russian-born father, an industrial chemist, had settled. Both his parents were Jewish.Missing: background | Show results with:background
  11. [11]
    Ernst Boris Chain | Department of Biochemistry
    Department of Biochemistry PhD student (1933-1935). Ernst Chain was born in Berlin in 1906 where his father had established a chemical factory. With this ...Missing: life | Show results with:life<|control11|><|separator|>
  12. [12]
    Sir Ernst Boris Chain | RCP Museum
    After studying at the Luisengymnasium, Ernst Chain entered the Friedrich-Wilhelm University, Berlin, in 1924, where he graduated in chemistry and physiology, ...Missing: education | Show results with:education
  13. [13]
    Ernst Chain—Nobel Prize for Work on Penicillin
    He attended the Luisen Gymnasium and then the Friedrich Wilhelm University of Berlin, obtaining a PhD degree in chemistry and physiology in 1930.Missing: biography education
  14. [14]
    Material relating to Ernst Chain and Anne Beloff-Chain - Archives Hub
    Ernst Boris Chain (1906-1979) was born in Berlin, of Russian-German-Jewish descent. His father, Michael Chain, was a chemist and industrialist who died when ...Missing: siblings | Show results with:siblings<|separator|>
  15. [15]
    Papers of: Chain, Sir Ernst Boris (1906-1979) - Archives Hub - Jisc
    In 1933 Chain became one of the many refugees from Nazi Germany, finding refuge in Britain. From 1933 to 1935 he worked in Cambridge at the School of ...Missing: emigration | Show results with:emigration
  16. [16]
    Who was Sir Ernst Chain? - Connaught Telegraph
    Oct 6, 2017 · His family was Jewish. His father emigrated from Russia to study chemistry abroad and his mother was from Berlin. In 1930, he received his ...
  17. [17]
    obituary - Nature
    University College London, Chain had the good fortune to be recommended by J.B.S.. Haldane to Sir Frederick Gowland. Hopkins, then Head of the Sir William.<|separator|>
  18. [18]
    Ernst Chain: a great man of science - PubMed
    Jun 22, 2013 · Chain directed the microbiological methods for producing penicillin and the chemical engineering methods to extract the material.
  19. [19]
    The Discovery of Penicillin—New Insights After More Than 75 Years ...
    At Oxford University, Ernst Chain found Fleming's 1929 article on penicillin and proposed to his supervisor, Howard Florey, that he try to isolate the compound.
  20. [20]
    Penicillin: the Oxford story
    Jul 16, 2010 · Florey and Chain began work on penicillin in 1939, says Eric. 'They quickly confirmed Fleming's findings and began to purify the substance.' ...
  21. [21]
    Alexander Fleming Discovery and Development of Penicillin
    It was Howard Florey, Ernst Chain and their colleagues at the Sir William Dunn School of Pathology at Oxford University who turned penicillin from a laboratory ...
  22. [22]
    Antibacterial Warfare: The Production of Natural Penicillin and the ...
    This commentary examines the participation of military medical services in the wartime development of mass-produced natural penicillin by fermentation ...
  23. [23]
    [PDF] Fact Sheet: The Challenge of Mass Production
    Chain began by purifying and concentrating the penicillin “juice” through a complex and tiring process of freeze drying the product repeatedly.
  24. [24]
    Timeline of key events in antimicrobial resistance
    15 Mar 1941, First patient treated with purified penicillin died, Florey, Chain, Healey ; January 1943 - May 1943, 400 million units of penicillin produced.<|separator|>
  25. [25]
    Rethinking Antibiotic Research and Development: World War II and ...
    Heralding a new phase in the history of the pharmaceutical industry, the WPB released penicillin for commercial distribution to the public in March 1945.Missing: timeline | Show results with:timeline
  26. [26]
    Penicillin: The War-Time Miracle Drug That Saved Millions - IBMS
    Nov 22, 2024 · The mass production of penicillin during WWII not only saved millions of lives but also laid the foundation for modern pharmaceuticals.Missing: applications | Show results with:applications
  27. [27]
    Nobel Laureates in Medicine | Nature
    The Nobel Prize for Medicine for 1945 has been awarded jointly to Sir Alexander Fleming, Sir Howard Florey and Dr. E. Chain.
  28. [28]
    Physiology or Medicine 1945 - Presentation Speech - NobelPrize.org
    Dr. Ernst Boris Chain, a chemist, took part in the final stage of these investigations, and during 1938 the two researchers jointly decided to investigate other ...Missing: biography | Show results with:biography
  29. [29]
    Ernst B. Chain
    Prize share: ⅓ - for the discovery of penicillin and its curative effect in various infectious diseases. Ernst Boris Chain. Given name. Ernst B. Family name.
  30. [30]
    The real story behind penicillin | PBS News
    Sep 27, 2013 · Ernst Chain, a Jewish German émigré. Chain was an abrupt, abrasive and acutely sensitive man who fought constantly with Florey over who ...Missing: methods | Show results with:methods<|separator|>
  31. [31]
    Building a penicillin production plant in post-war Italy
    In 1947, Ernst Chain moved from Oxford to Rome, hired as head of a new biochemistry department and of a penicillin production pilot plant in the Istituto ...
  32. [32]
    Sir Ernst Chain is honoured in building naming ceremony
    Nov 5, 2012 · Imperial celebrates the founder of the Department of Biochemistry as it names the Sir Ernst Chain Building Wolfson Laboratories.
  33. [33]
    Ernst Boris Chain. 19 June 1906-12 August 1979 - jstor
    Istituto Superiore di Sanita. There can be no doubt that it pointed to a need for a major reform in the handling of scientific research by the. Italian ...<|separator|>
  34. [34]
    CHAIN, Ernst Boris - Centre for Scientific Archives
    Sep 13, 2023 · E.B. Chain CSAC 92/3/83 14 Biographical and personal A.14 Chain's Doctorate in absentia from Friedrich-Wilhelms- Universitdt, Berlin, May 1933.<|separator|>
  35. [35]
    Ernst Boris Chain | Encyclopedia.com
    Chain, Sir Ernst Boris (1906–79) German-born British biochemist, who began his research career at Cambridge University in 1933. Two years later he joined ...
  36. [36]
    Practicing biochemistry without a licence? - PMC - PubMed Central
    ... Ernst Chain, refused to appoint any molecular biologists to staff, and on ... Molecular biology is, after all, just what it says on the tin: a study of ...
  37. [37]
    Obituary
    Ernst Chain was a gifted man who spoke fluently in several languages. He ... ing the rise of molecular biology; and he believed in a close relationship ...
  38. [38]
    NPG 5989; Sir Ernst Chain - Portrait
    When Chain emigrated to Britain, his mother and sister remained in Germany and were later murdered in Nazi concentration camps. The artist Lotte Laserstein ...
  39. [39]
    Ernst Boris Chain - Bionity
    His views were expressed most clearly in his speech 'Why I am a Jew' given ... Ernst Chain / Howard Florey (1945) • Hermann Muller (1946) • Carl Cori ...
  40. [40]
    Penicillin & Chicken Soup | hgoldmeier - WordPress.com
    Feb 27, 2017 · The truly great scientific advance began when German-Jewish biochemist Ernst Chain ... In “Why I Am a Jew,” a speech he delivered at the World ...
  41. [41]
    Ernst Chain 'Science, as long as it limits itself to the descriptive study ...
    OCR: 'Science, as long as it limits itself to the descriptive study of the laws has no of nature moral quality.' or ethical - Ernst -ErnstChain Ernst Chain ...<|control11|><|separator|>
  42. [42]
    Antibiotic Cold War and Ernst Chain's Visit to China in 1961
    Sep 17, 2024 · This article illustrates the PRC's predicament on antibiotics and its efforts to escape from it, elaborates Chain's visit and the British response.
  43. [43]
    Ernst B. Chain - NNDB
    Born: 19-Jun-1906 ; Birthplace: Berlin, Germany ; Died: 12-Aug-1979 ; Location of death: Castlebar, Ireland ; Cause of death: Heart Failure.
  44. [44]
    Ernst Chain: Antibiotics Pioneer | The Institute for Creation Research
    Apr 1, 2008 · In 1940 he also discovered penicillinase, an enzyme that is used by bacteria to inactivate penicillin, negating its effectiveness.12 Chain knew ...
  45. [45]
    Florey and Chain Develop Penicillin as an Antibiotic - EBSCO
    Baron Florey and Ernst Boris Chain concentrated and clinically tested penicillin, the first successful and widely used antibiotic drug. Locale Oxford, England ...
  46. [46]
    The Penicillin Pioneer: Alexander Fleming's Journey to a Medical ...
    The report also highlights the crucial contributions of Howard Florey, Ernst Boris Chain, and Norman Heatley in developing penicillin into a widely usable ...<|control11|><|separator|>
  47. [47]
    Sir Ernst Boris Chain | Nobel Prize, Penicillin & Antibiotic Research
    Oct 1, 2025 · German-born British biochemist who, with pathologist Howard Walter Florey, isolated and purified penicillin (which had been discovered in 1928 by Sir Alexander ...